Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A novel autopolysialylation activity of the ganglioside sialyltransferase ST8Sia5 regulates its secretion and enzyme activity

ABSTRACT: This study showed that ST8Sia5L is a novel self-polysialylating enzyme that modifies itself rather than NCAM. We found that this autopolysialylation regulates both the secretion of ST8Sia5L from cells and its conventional ganglioside-sialylation activity. These results suggest that polysialylation of ST8Sia5L plays an important role in controlling its function and extracellular behavior.

ORGANISM(S): Mus musculus

PROVIDER: GSE327613 | GEO | 2026/06/18

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

A novel autopolysialylation activity of the ganglioside sialyltransferase ST8Sia5 regulates its secretion and enzyme activity

Project description:A novel autopolysialylation activity of the ganglioside sialyltransferase ST8Sia5 regulates its secretion and enzyme activity

| PRJNA1451527 | ENA

SialidaseNeu3action on GM1 ganglioside is neuroprotective in GM1 Gangliosidosis

Project description:GM1 gangliosidosis is a neurodegenerative disorder caused by mutations in theGLB1gene, which encodes lysosomalb-galactosidase. The enzyme deficiency blocks GM1 ganglioside catabolism, leading to accumulation of GM1 ganglioside and asialo-GM1 ganglioside (GA1 glycolipid) in brain. This disease can present in varying degrees of severity, with the level of residualb-galactosidase activity primarily determining the clinical course.Glb1null mouse models, which completely lackb-galactosidase expression, exhibit a less severe form of the disease than expected from the comparable deficiency in humans, suggesting a potential species difference in the GM1 ganglioside degradation pathway. We hypothesized this difference may involve the sialidase NEU3, which acts on GM1 ganglioside to produce GA1 glycolipid. To test this hypothesis, we generatedGlb1/Neu3double knockout (DKO) mice. These mice had a significantly shorter lifespan, increased neurodegeneration, and more severe ataxia thanGlb1KO mice.Glb1/Neu3DKO mouse brains exhibited an increased GM1 ganglioside to GA1 glycolipid ratio compared withGlb1KO mice, indicating that Neu3 mediated GM1 ganglioside to GA1 glycolipid conversion inGlb1KO mice. The expression of genes associated with neuroinflammation and glial responses were enhanced inGlb1/Neu3DKO mice compared withGlb1KO mice. Mouse Neu3 more efficiently converted GM1 ganglioside to GA1 glycolipid than human NEU3 did. Our findings highlight Neu3’s role in ameliorating the consequences ofGlb1deletion in mice, provide insights into NEU3’s differential effects between mice and humans in GM1 gangliosidosis, and offer a potential therapeutic approach for reducing toxic GM1 ganglioside accumulation in GM1 gangliosidosis patients.

2023-12-14 | GSE241844 | GEO

Differential regulation of genes in response to exogenous ganglioside GM2 treatment in Cancer cells.

Project description:Gangliosides have been implicated in various diseases including but not limited to cancer. Overexpression of one of these gangliosides, namely ganglioside GM2 has been associated with several cancers like Glioblastoma (GBM), Renal Cell Carcinoma (RCC) and several others. Despite the definite role of GM2 in tumor-induced host immune suppression has been extensively studied, not much was known regarding its involvement in the alteration of tumor cell behaviour. Our laboratory established that ganglioside GM2 plays a pivotal role in promoting migration and invasion of cancer cells and in inducing epithelial-mesenchymal transition (EMT) primarily by acquiring anoikis resistance and anchorage independence. Our initial data indicates that GM2's pro-tumorigenic function may be elaborated through modulation of a diverse, yet distinct signaling pathways. To address this, we undertook this task of mapping the differential regulation of genes in response to exogenous GM2 treatment in HeLa cells.

2025-12-31 | GSE296987 | GEO

SialidaseNeu3action on GM1 ganglioside is neuroprotective in GM1 Gangliosidosis

Project description:SialidaseNeu3action on GM1 ganglioside is neuroprotective in GM1 Gangliosidosis

| PRJNA1010227 | ENA

The ganglioside GM3 protects against abdominal aortic aneurysm by suppressing ferroptosis in vascular smooth muscle cells

Project description:This project provides insights into the role of ganglioside GM3 in the pathogenesis of abdominal aortic aneurysm (AAA).

2023-09-06 | PXD045177 |

Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies

Project description:Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies

| PRJNA391729 | ENA

Gene expression profiling of NCAM-deficient mouse brain

Project description:Analysis of brains of mice lacking the neural cell adhesion molecule NCAM (Ncam-/-) in comparison to wild-type mice of same age and genetic background (Ncam+/+). NCAM-deficient mice exhibit deficits in long-term potentiation and spatial learning, as well as increased intermale aggression. We performed a microarray analysis of adult NCAM-deficient mouse brains to identify molecular targets which might underly the phenotype of NCAM-deficient mice.

2009-12-01 | GSE16647 | GEO

Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies I

Project description:Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies I

| PRJNA391733 | ENA

Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies V

Project description:Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies V

| PRJNA391737 | ENA

Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies VI

Project description:Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies VI

| PRJNA391738 | ENA